Price movement over the last 24 hours
Alcon AG vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Alcon AG trades at $66.84 (market cap $32.69B), while T-Rex 2X Long MSTR Daily Target ETF trades at $1.86. The key difference: Alcon AG pays a 0.54% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none, and Alcon AG is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| ALC | MSTU | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $92.22 | $106.80 |
52-Week Low | $62.02 | $1.46 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
MSTU trades at $2.15, unchanged on the day, with a bearish technical outlook indicated by moving averages and ADX signals. The ETF has experienced extreme volatility, with news reports highlighting a 95% annual decline. Key support and resistance are at $2 and $3, respectively. Financial ratios are unavailable, and the fund's performance is directly tied to the daily moves of its underlying asset.
The outlook for MSTU is highly speculative and carries significant risk due to its leveraged structure, which can amplify losses. Investor sentiment is negative following substantial historical declines. Any investment is a high-risk bet on short-term price movements of the underlying asset, not a long-term fundamental holding.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →